About Stratos Genomics
Stratos Genomics is a company based in Seattle (United States) founded in 2007 was acquired by Roche in May 2020. Stratos Genomics has raised $62.89 million across 10 funding rounds from investors including Roche, HHS and NHGRI. The company has 64 employees as of December 31, 2022. Stratos Genomics operates in a competitive market with competitors including Nanopore, Cepheid, PacBio, Omniome and Complete Genomics, among others.
- Headquarter Seattle, United States
- Employees 64 as on 31 Dec, 2022
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stratos Genomics Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Stratos Genomics
Unlock access to complete
Unlock access to complete
Leadership Team
62 people
Software Development Team
54 people
Human Resources and Administration
40 people
Finance and Accounting
37 people
Operations Team
36 people
Product Management Team
31 people
Sales and Marketing
22 people
Senior Team
19 people
Unlock access to complete
Funding Insights of Stratos Genomics
Stratos Genomics has successfully raised a total of $62.89M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $20.16 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Stratos Genomics
Stratos Genomics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, HHS and NHGRI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital firm focused on the healthcare sector
|
Locked | Locked | Locked | |
|
High-growth investments are created and managed via equity development.
|
Locked | Locked | Locked | |
|
Genomics research and educational resources are provided.
|
Locked | Locked | Locked |
Investor details for Stratos Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stratos Genomics
Investment portfolio details for Stratos Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Stratos Genomics
Detailed financials for Stratos Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stratos Genomics Comparisons
Peer comparison for Stratos Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stratos Genomics
Stratos Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nanopore, Cepheid, PacBio, Omniome and Complete Genomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| Locked | Locked | Locked |
Developer of molecular diagnostic testing solutions
|
|
| Locked | Locked | Locked |
Instrument systems and software for single-molecule real-time sequencing are developed.
|
|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
DNA sequencing platform for human genome analysis is developed.
|
|
| Locked | Locked | Locked |
Handheld diagnostic and sequencing devices are developed for personalized healthcare.
|
Detailed competitors of Stratos Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stratos Genomics
Complete news archive for Stratos Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stratos Genomics
Stratos Genomics was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Stratos Genomics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Stratos Genomics is a funded company, having raised a total of $62.89M across 10 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Stratos Genomics is 64.
Stratos Genomics was founded in 2007 in Seattle, United States, and operates in the biotechnology sector focused on genomic sequencing. The companys core technology, Sequencing By Expansion (SBX), involves the conversion of DNA into an expanded polymer called an xpandomer through a polymerase-mediated process. Modified polymerases incorporate four-base Xprobes with reporter molecules, enabling the xpandomer to be threaded through a solid-state nanopore for sequence detection based on reporter signals.
Stratos Genomics has 5 investors. Key investors include Roche, HHS, NHGRI, Stratos Group, and Roche.